Single-dose daily infusion of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors

International Journal of Hematology

Volumn 83, Issue 2, 2006, Pages 159-163

  Nawa, Yuichiro ^a   Hara, Masamichi ^a   Tanimoto, Kazushi ^a   Nakase, Koichi ^a   Kozuka, Teruhiko ^a   Maeda, Yoshinobu ^a  

^a EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

CsA; Graft versus host disease; Matched unrelated donor; Short infusion

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DNA; FLUCONAZOLE; GANCICLOVIR; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; LEVOFLOXACIN; METHOTREXATE; CYCLOSPORIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HYPERTENSION; MALE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; SINGLE DRUG DOSE; T CELL LEUKEMIA; T CELL LYMPHOMA; TREMOR; ALLELE; ALLOTRANSPLANTATION; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DONOR; IMMUNOLOGY; KIDNEY DISEASE; METHODOLOGY; MIDDLE AGED; PHARMACOKINETICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALLELES; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; PHARMACOKINETICS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33646825995     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05006     Document Type: Article

References (29)

1. Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute graft-versus-host disease: the old and the new-a report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant. 1997;19:577-600.
2. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
3. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
4. Sindhi R, LaVia MF, Pasulling E, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation. 2000;69:432-436.
5. Quien RM, Kaiser BA, Dunn SP, et al. Calcineurin activity in children with renal transplants receiving cyclosporine. Transplantation. 1997;64:1486-1489.
6. Batiuk TD, Pazderka F, Holloran PF. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation. 1995;59:1400-1404.
7. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring superior to trough level monitoring. Ther Drug Monit. 1989;11:246-248.
8. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling of monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-486.
9. Pollard SG, Lear PA, Ready AR, Moore RH, Johnson RW. Comparison of microemulsion and conventional formulations of cyclosporine in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group. Transplantation. 1999;68:1325-1331.
10. Graziadei IW, Wiesner RH, Marotta PJ, et al. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation. Transplantation. 1997;64:726-731.
11. Ogawa N, Kanda Y, Matsubara M, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant. 2004;33:549-552.
12. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class 1 HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177-1185.
13. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
14. Beelen DW, Quabeck K, Kaiser B, et al. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1990;50:421-427.
15. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A,B,DR identical unrelated donor marrow transplantation. Blood. 1995;86:1606-1613.
16. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200-4206.
17. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-2314.
18. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-2068.
19. Miller KB, Schenkein DP, Comezo R, et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994;68:15-20.
20. Schultz KR, Nevill TJ, Balshaw RF, et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant. 2000;26:545-551.
21. Dotti G, Gaspari F, Caruso R, et al. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. Haematolgica. 2001;86:311-315.
22. Schwinghammer TL, Przepiorka D, Venkataramanan R, et al. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. Br J Clin Pharmacol. 1991;32:323-328.
23. Parquet N, Reigneau O, Humbert H, et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2000;25:965-968.
24. Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ. Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol. 1994;34:60-67.
25. Ogata M, Ogata Y, Imamura T, et al. Successful bone marrow transplantation from an unrelated donor in a patient with adult T cell leukemia. Bone Marrow Transplant. 2002;30:699-701.
26. Ljungman P, Lawler M, Asjo B, et al. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-1) following allogeneic bone marrow transplantation for HTLV-1 positive adult T-cell leukemia. Br J Haematol. 1994;88:403-405.
27. Ringlen O, Labopin M, Tura S, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996;93:637-645.
28. Tallman MS, Nemunaitis JJ, Mc Guire TR, et al. Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients. Transplantation. 1985;45:813-817.
29. Tarantino A, Passerini P, Campise M, et al. Is cyclosporine in renaltransplant recipients more effective when given twice a day than in a single daily dose? Transplantation. 2004;78:675-680.